课题基金 / 基金详情

The IL-6 Induced Retinal Iron Sequestration Response

The IL-6 Induced Retinal Iron Sequestration Response
IL-6 诱导的视网膜铁螯合反应
批准号:
10281696
负责人:
JOSHUA L DUNAIEF
金额:
$40.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-06-01 至 2024-05-31

项目摘要

项目成果

JOSHUA L DUNAIEF的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT The goal of the proposed studies is to define an IL6 triggered cellular iron sequestration response (CISR) in a mouse model of Alzheimer's Disease (AD). Iron is necessary for growth and survival for all life forms, so cellular iron uptake and sequestration is a mechanism that limits the growth of extracellular bacteria. However, when the CISR is maladaptively activated by chronic neuroinflammation, the resulting iron accumulation can be toxic to the CNS. Toxic iron accumulation and dysregulation have been implicated in AD pathogenesis, and an ongoing phase 2 clinical trial is evaluating an iron chelator in AD patients (NCT03234686). However, understanding the mechanisms leading to iron dysregulation, and the brain cell types affected is likely to lead to a more targeted therapy than iron chelation. Evidence implicating an IL6 induced CISR in AD pathogenesis includes: 1)AD brains have iron dysregulation, with iron accumulation in plaques 2) AD brains have elevated IL6 levels near plaques. overexpressing elevated neurodegeneration Brain as in 3)A transgenic mouse IL6 i n astrocytes has brain iron accumulation. 4)The 5XFAD mouse model of AD has brain iron levels and CISR activation. 5) The iron chelator deferoxamine can ameliorate the phenotype of the AD mode l App/Ps1, another model driven by Aβ deposition. 6) iron dysregulation is also associated with Parkinson's Disease and t he hereditary diseases classified Neurodegenerations with Brain Iron Overload (NBIA). Understanding the role of the IL6 induced CISR AD pathogenesis is thus likely to lead to novel therapeutics for patients suffering from this disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The IL-6 Induced Retinal Iron Sequestration Response
  • 批准号:
    10416008
  • 项目类别:
  • 资助金额:
    $38.92万
  • 财政年份:
    2019
  • 负责人:
    JOSHUA L DUNAIEF
  • 依托单位:
The IL-6 Induced Retinal Iron Sequestration Response
  • 批准号:
    10636913
  • 项目类别:
  • 资助金额:
    $40.12万
  • 财政年份:
    2019
  • 负责人:
    JOSHUA L DUNAIEF
  • 依托单位:
Novel Iron Prochelators for Protection Against Oxidative Stress in RPE Cells
  • 批准号:
    7451925
  • 项目类别:
  • 资助金额:
    $24.95万
  • 财政年份:
    2008
  • 负责人:
    JOSHUA L DUNAIEF
  • 依托单位:
Novel Iron Prochelators for Protection Against Oxidative Stress in RPE Cells
  • 批准号:
    7577522
  • 项目类别:
  • 资助金额:
    $19.59万
  • 财政年份:
    2008
  • 负责人:
    JOSHUA L DUNAIEF
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: